RE: GlyMab platform12 Dec 2024 11:49
Morning ,
My opinion is Scancell will continue to develop the GlyMab platform , it’s in its infancy but has huge income potential and could add a substantial price tag if/when the company gets bought out and I also believe this to be the case with the Moditope platform .
I can see however the Scib/Iscib platform being sold if the price is right after the full set of results are in in 2025 , it maybe a case they continue through to phase 3 with a partner but if they sell the platform that puts any funding concerns to bed and allows the company to concentrate on the other two platforms with a substantial bank balance .
The recent raise frustrated me for all the reasons discussed but it’s better to have funds in the bank now than trying to raise funds later in a climate which is only going to get tougher .
Anyway it can’t of annoyed me that much because I bought a few more .